JP Morgan Chase
TXG icon

JP Morgan Chase’s 10x Genomics TXG Stock Holding History

JP Morgan Chase’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2M Sell
753,045
-32,460
-4% -$851K ﹤0.01% 1933
2026
Q1 		$15.6M Sell
785,505
-142,921
-15% -$2.86M ﹤0.01% 2295
2025
Q4 		$15.1M Sell
928,426
-145,439
-14% -$2.2M ﹤0.01% 2308
2025
Q3 		$12.6M Buy
1,073,865
+951,495
+778% +$12.4M ﹤0.01% 2519
2025
Q2 		$1.42M Sell
122,370
-80,520
-40% -$734K ﹤0.01% 4157
2025
Q1 		$1.77M Sell
202,890
-94,012
-32% -$1.19M ﹤0.01% 3964
2024
Q4 		$4.26M Sell
296,902
-58,586
-16% -$925K ﹤0.01% 3488
2024
Q3 		$8.03M Buy
355,488
+277,355
+355% +$5.73M ﹤0.01% 2805
2024
Q2 		$1.52M Sell
78,133
-1,301
-2% -$34.1K ﹤0.01% 3988
2024
Q1 		$2.98M Sell
79,434
-1,395,852
-95% -$61.3M ﹤0.01% 3517
2023
Q4 		$82.6M Buy
1,475,286
+243,124
+20% +$10.6M 0.01% 983
2023
Q3 		$50.8M Sell
1,232,162
-111,170
-8% -$5.78M 0.01% 1113
2023
Q2 		$75M Buy
1,343,332
+70,597
+6% +$3.82M 0.01% 953
2023
Q1 		$71M Buy
1,272,735
+10,835
+0.9% +$506K 0.01% 938
2022
Q4 		$46M Buy
1,261,900
+55,496
+5% +$1.81M 0.01% 1160
2022
Q3 		$34.4M Buy
1,206,404
+196,482
+19% +$7.49M ﹤0.01% 1243
2022
Q2 		$45.7M Buy
1,009,922
+926,161
+1,106% +$48.1M 0.01% 1088
2022
Q1 		$6.37M Sell
83,761
-63,593
-43% -$5.56M ﹤0.01% 2787
2021
Q4 		$21.9M Sell
147,354
-80,199
-35% -$12.3M ﹤0.01% 1746
2021
Q3 		$33.1M Buy
227,553
+181,175
+391% +$31.1M ﹤0.01% 1405
2021
Q2 		$9.08M Sell
46,378
-55,867
-55% -$10.1M ﹤0.01% 2505
2021
Q1 		$18.5M Sell
102,245
-46,057
-31% -$7.95M ﹤0.01% 1823
2020
Q4 		$21M Sell
148,302
-35,942
-20% -$5.22M ﹤0.01% 1580
2020
Q3 		$23M Sell
184,244
-91,456
-33% -$9.6M ﹤0.01% 1413
2020
Q2 		$24.6M Buy
275,700
+31,443
+13% +$2.45M ﹤0.01% 1241
2020
Q1 		$15.2M Sell
244,257
-25,049
-9% -$1.95M ﹤0.01% 1439
2019
Q4 		$20.5M Buy
269,306
+54,155
+25% +$3.26M ﹤0.01% 1572
2019
Q3 		$10.8M Buy
+215,151
New +$11.9M ﹤0.01% 2081

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's TXG Position: Q2 2026 in Review

JP Morgan Chase reduced its 10x Genomics (TXG) stake by 4.1% in Q2 2026, selling an estimated $851K and leaving 753,045 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

JP Morgan Chase first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $82.6M in Q4 2023. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • JP Morgan Chase held 753,045 shares of 10x Genomics worth $28.2M as of Q2 2026.
  • JP Morgan Chase sold 32,460 10x Genomics shares in Q2 2026, an estimated $851K.
  • 10x Genomics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1933 holding.
  • JP Morgan Chase first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's 10x Genomics position peaked at $82.6M in Q4 2023.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.